BAY 1895344 clinical trials
Also written BAY 1895344 and Elimusertib.
- studies test it
- 9
- open now
- 0
- in phase 3
- 0
- first study started
- 2017
How each study uses BAY 1895344 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorisations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
9 studies that test it; most in 2021 (4)
| Year | Studies |
|---|---|
| 2017 | 1 |
| 2019 | 1 |
| 2020 | 1 |
| 2021 | 4 |
| 2022 | 2 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 3 · Other 6
National Cancer Institute (NCI) (5) · Bayer (3) · M.D. Anderson Cancer Center (1)
Often tested with
Tested in the same studies.
Related medicines
As reviewed, each with the page that says it.
- One of Protein Kinase Inhibitors source
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 1
Studies that test BAY 1895344.
- Jun 2027Testing the Addition of an Anti-cancer Drug, BAY 1895344, to the Usual Chemotherapy Treatment (Cisplatin, or Cisplatin and Gemcitabine) for Advanced Solid Tumors With Emphasis on Urothelial CancerPhase 1 · National Cancer Institute (NCI)
Studies
Open first, then newest update. How each study uses BAY 1895344 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 9
- Testing the Addition of an Anti-cancer Drug, BAY 1895344, With Radiation Therapy to the Usual Pembrolizumab Treatment for Recurrent Head and Neck CancerActive, not recruitingPhase 1National Cancer Institute (NCI)NCT04576091Written as Elimusertib
- Testing the Addition of an Anticancer Drug, BAY 1895344, to the Usual Chemotherapy With FOLFIRI in Advanced or Metastatic Cancers of the Stomach and IntestinesActive, not recruitingPhase 1National Cancer Institute (NCI)NCT04535401Written as Elimusertib
- Testing the Addition of an Anti-cancer Drug, Elimusertib (BAY 1895344) ATR Inhibitor, to the Chemotherapy Treatment (Gemcitabine) for Advanced Pancreatic and Ovarian Cancer, and Advanced Solid TumorsActive, not recruitingPhase 1National Cancer Institute (NCI)NCT04616534Written as Elimusertib
- Testing the Addition of an Anti-cancer Drug, BAY 1895344, to the Usual Chemotherapy Treatment (Cisplatin, or Cisplatin and Gemcitabine) for Advanced Solid Tumors With Emphasis on Urothelial CancerActive, not recruitingPhase 1National Cancer Institute (NCI)NCT04491942Written as Elimusertib
- Elimusertib for the Treatment of Relapsed or Refractory Solid TumorsActive, not recruitingPhase 1/2National Cancer Institute (NCI)NCT05071209Written as Elimusertib
- Study to Test How Well Patients With Advanced Solid Tumors Respond to Treatment With the Elimusertib in Combination With Pembrolizumab, to Find the Optimal Dose for Patients, How the Drug is Tolerated and the Way the Body Absorbs, Distributes and Discharges the DrugCompletedPhase 1BayerNCT04095273Written as Elimusertib (BAY1895344)
- ATR Inhibitor Elimusertib (BAY1895344) Plus Niraparib Phase 1b Study in Advanced Solid Tumors and Ovarian CancerTerminatedPhase 1BayerNCT04267939Written as Elimusertib (BAY1895344)
- First-in-human Study of ATR Inhibitor BAY1895344 in Patients With Advanced Solid Tumors and LymphomasCompletedPhase 1BayerNCT03188965Written as Elimusertib (BAY1895344)
- BAY1895344 and Copanlisib for the Treatment of Molecularly Selected Patients With Advanced Solid TumorsWithdrawnPhase 1M.D. Anderson Cancer CenterNCT05010096Written as Elimusertib
Given beside what is tested · 1 — BAY 1895344 is usual care or a partner of the new treatment
Codes
What other systems call BAY 1895344 · ClinicalTrials.gg INT001455
- MeSH (NLM) C000711582BAY 1895344One source ClinicalTrials.gov
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000711582 | BAY 1895344 | One source ClinicalTrials.gov |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.